Perspective Therapeutics CATX Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Viridian Therapeutics, Inc.VRDN

——

PrecigenPGEN

——

Spyre Therapeutics, Inc.SYRE

——

Other financials

Income statement

See full

Revenue$2.2M+27.3%

Gross profit$738.0K+78.3%

Operating income-$28.3M-29.5%

Net income-$26.2M-44.1%

EPS (diluted)-$0.250.0%

Balance sheet

See full

Cash & equivalents$54.0M+21.5%

Total debt$4.2M+10.9%

Total equity$347.4M+22.1%

Total assets$410.8M+24.7%

Cash flow

See full

Operating cash flow-$31.5M-45.8%

CapEx$6.9M+47.3%

Free cash flow-$38.3M-46.1%

Valuation

See full

Market cap$342.14M+33.2%

Enterprise value$292.34M+35.2%

P/S34.2×+19.6×

Profitability

See full

Gross margin33.1%-7.1pp

Operating margin-292.7%-553pp

Net margin-218.4%-781pp

FCF margin-1,073.3%—

Returns & leverage

See full

Return on equity-35.2%+2.3pp

Debt / equity0×0.0×

Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Perspective Therapeutics's proceeds from sale and maturity of available for sale securities?: Perspective Therapeutics (CATX) reported proceeds from sale and maturity of available for sale securities of $47.64M in Q1 2026.
How has Perspective Therapeutics's proceeds from sale and maturity of available for sale securities changed year-over-year?: Perspective Therapeutics's proceeds from sale and maturity of available for sale securities increased by 119.5% year-over-year, from $21.7M to $47.64M.